|
|
|
|
| LEADER |
01707nam a2200217 u 4500 |
| 001 |
EB002219846 |
| 003 |
EBX01000000000000001356807 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
240703 r ||| eng |
| 245 |
0 |
0 |
|a Comparative clinical and cost-effectiveness of drug therapies for relapsing-remitting multiple sclerosis
|h Elektronische Ressource
|b project protocol
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2012, December 2012
|
| 300 |
|
|
|a 1 PDF file (8 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH therapeutic review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK361336
|3 Volltext
|
| 082 |
0 |
|
|a 800
|
| 520 |
|
|
|a The Canadian Agency for Drugs and Technologies in Health (CADTH) will undertake a systematic review to compare the efficacy and safety of disease-modifying agents for patients with relapsing-remitting multiple sclerosis (RRMS), and will examine their cost-effectiveness. The review will include disease-modifying agents that are currently available in Canada (interferon beta-1a and -1b, natalizumab, glatiramer acetate, fingolimod), and a number of agents that are newly emerging and not yet approved in Canada (teriflunomide, dimethyl fumarate, and alemtuzumab). The systematic review and cost-effectiveness evidence will be reviewed by the Canadian Drug Expert Committee (CDEC) for the purpose of making recommendations. Recommendations and advice provided by CDEC are provided to CADTH to inform participating jurisdictions
|